Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients

Recruiting N/A Interventional Study
Glioblastoma Meningeal Arteries
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 70
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
20 (estimated)
Sponsor
First Affiliated Hospital, Sun Yat-Sen University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Glioblastoma is the most common primary malignancy of the central nervous system with a very poor prognosis. Most of the immunotherapies that have made significant breakthroughs in the treatment of other tumors in recent years are unsatisfactory in the application of glioblastoma, which is mainly inseparable from the highly inhibitory immune microenvironment formed by the latter. Therefore, how to…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Imaging or needle biopsy pathologically diagnosed as glioblastoma * Patients have not previously received radiotherapy, chemotherapy and other treatment modalities for intracranial lesions * There are no related contraindications such as neurovascular intervention and cranioto…
Contacts

Nu Zhang, Professor

13825070717

zhangnu2@mail.sysu.edu.cn

CONTACT

Kejun He, Attending

15920463410

mailto:hekejun3@ms.sysu.edu.cn

CONTACT